Johnson & Johnson $JNJ Position Increased by University of Texas Texas AM Investment Management Co.

University of Texas Texas AM Investment Management Co. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 844.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,389 shares of the company’s stock after acquiring an additional 46,841 shares during the period. Johnson & Johnson comprises approximately 1.3% of University of Texas Texas AM Investment Management Co.’s portfolio, making the stock its 15th biggest holding. University of Texas Texas AM Investment Management Co.’s holdings in Johnson & Johnson were worth $8,002,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. GFG Capital LLC bought a new position in Johnson & Johnson during the second quarter valued at about $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC bought a new position in Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the first quarter valued at about $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 1.1%

JNJ stock opened at $190.38 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a market cap of $458.69 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The business’s 50-day simple moving average is $182.26 and its 200 day simple moving average is $166.37. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Ratings Changes

Several equities analysts have weighed in on JNJ shares. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Stifel Nicolaus raised their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. Argus set a $210.00 price target on Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $199.05.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.